Factors influencing in-hospital delay in treatment with intravenous thrombolysis

Stroke

Volumn 43, Issue 6, 2012, Pages 1578-1583

  Mikulík, Robert ^a   Kadlecová, Pavla ^a   Czlonkowska, Anna ^b,c   Kobayashi, Adam ^b   Brozman, Miroslav ^d   Švigelj, Viktor ^e   Csiba, Laszlo ^f   Fekete, Klara ^f   Kõrv, Janika ^g   Demarin, Vida ^h   Vilionskis, Aleksandras ⁱ   Jatuzis, Dalius ⁱ   Krespi, Yakup ^j   Ahmed, Niaz ^k,l  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d University Hospital Nitra   (Slovakia)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g UNIVERSITY OF TARTU   (Estonia)

^h SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

ⁱ VILNIUS UNIVERSITY   (Lithuania)

^j ISTANBUL BILIM UNIVERSITY   (Turkey)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

acute stroke; admission to treatment time; door to needle time; organized stroke care; stroke care; thrombolysis

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; DOOR TO NEEDLE TIME; FEMALE; HEALTH CARE DELIVERY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; ONSET TO DOOR TIME; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; RESIDENTIAL AREA; STROKE; THERAPY DELAY;

AGE FACTORS; AGED; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 84861592848     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.644120     Document Type: Article

References (15)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA stroke study group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
4. Safe Implementation of Thrombolysis in Stroke-International Stroke Register. Available at https://sitsinternational.org. Accessed October 19, 2011.
5. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITSISTR): an observational study. Lancet. 2008;372:1303-1309.
6. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees RK, Mikulik R, et al. Implementation and outcome of thrombolysis in the 3-4.5-h window-17 months' experience after the ECASS III trial and SITS study: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9:866-874.
7. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
8. Karlinski M, Kobayashi A, Mikulik R, Sanak D, Wahlgren N, Czlonkowska A. Intravenous alteplase in ischaemic stroke patients not fully adhering to the current drug license in central and eastern Europe. Int J Stroke. Published ahead of print February 7, 2012. DOI: 10.1111/j.1747-4949.2011.00733.x.
9. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study investigators. Lancet. 1998;352:1245-1251.
10. Ferrari J, Knoflach M, Kiechl S, Willeit J, Matosevic B, Seyfang L, et al. Stroke thrombolysis: having more time translates into delayed therapy: SATA from the Austrian stroke unit registry. Stroke. 2010; 41:2001-2004.
11. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750-758.
12. Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The 'golden hour' and acute brain ischemia: presenting features and lytic therapy in 30 000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41:1431-1439.
13. Bluhmki E, Chamorro Á, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8:1095-1102.
14. The NINDS tPA Stroke Study Group. Generalized efficacy of tPA for acute stroke. Subgroup analysis of the NINDS tPA stroke trial. Stroke. 1997;28:2119-2125.
15. Mishra NK, Lyden P, Grotta JC, Lees KR. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2612-2617.